Journal Basic Info

  • Impact Factor: 1.809**
  • H-Index: 6
  • ISSN: 2474-1655
  • DOI: 10.25107/2474-1655
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Medical Radiography
  •  Dermatology and Cosmetology
  •  Biochemistry and Biostatistics
  •  Psychiatry and Mental Health
  •  ENT
  •  Cardiovascular Medicine
  •  Vascular Medicine
  •  Forensic and Legal Medicine

Abstract

Citation: Ann Clin Case Rep. 2022;7(1):2232.DOI: 10.25107/2474-1655.2232

Rapid Improvement of Symptom Scores and QoL on Short- Term with Extrafine Fixed Triple Inhaled Therapy and Patient Characteristics in Moderate COPD in a Real-Life Setting

Tomisa G1,2*, Horváth A1,2, Sánta B1, Kovács T1, Szabó M3, Lovász O4, Müller V2 and Tamási L2

1Chiesi Hungary Ltd, Hungary 2Department of Pulmonology, Semmelweis University, Hungary 3Robert Koch Hospital and Outpatient Clinic, Hungary 4Health Centre and Outpatient Clinic of Komló, Hungary

*Correspondance to: Tomisa G 

 PDF  Full Text Research Article | Open Access

Abstract:

Aim: There is a lack of knowledge of the efficacy of single inhaler triple combination therapy in patients with moderate COPD. Subjects and Methods: RATIONALE is a 52-week, ongoing phase IV, multicentre, prospective clinical trial evaluating the efficacy of single inhaler triple therapy BDP/FF/GB in patients with moderate COPD. The main eligibility criteria were age ≥ 35 years, 50% ≤ FEV1 <80%, CAT score ≥ 10 or mMRC ≥ 2 and ≥ 2 exacerbations/year. Changes in the treatment of patients had to happen before and irrespective of study inclusion. A pre-planned interim analysis of the first two visits was conducted 1 year after the start of the study. Results: As of data cut-off (March 18th, 2021), 616 patients were enrolled in the study and 498 patients were included in this analysis. 91 patients (18.3%) had received ICS-LABA, 140 patients (28.1%) open triple combination and 267 (53.6%) patients LABA-LAMA as previous therapy. The proportion of patients not reporting cough/sputum production increased by 9.05% and 19.68%, respectively (p<0.0001). The proportion of patients not reporting any limitations increased in all EQ-5D-3L domains (p<0.0001). The average mMRC scores decreased significantly (p<0.0001). The mean values in the CAT and VAS scores improved in all FEV1 groups (p<0.0001). Conclusion: In this interim analysis, significant improvements were seen in all of the assessed parameters, showing a clear benefit for extrafine single inhaler triple therapy use in patients with moderate COPD who were symptomatic on previous dual or open triple therapy.

Keywords:

COPD; Fixed triple combination; Real-world study; Adherence; Symptom scores; Quality of life

Cite the Article:

Tomisa G, Horváth A, Sánta B, Kovács T, Szabó M, Lovász O, et al. Rapid Improvement of Symptom Scores and QoL on Short-Term with Extrafine Fixed Triple Inhaled Therapy and Patient Characteristics in Moderate COPD in a Real-Life Setting. Ann Clin Case Rep. 2022; 7: 2232..

Search Our Journal

Journal Indexed In

Articles in PubMed

Tocotrienols: Exciting Biological and Pharmacological Properties of Tocotrienols and other Naturally Occurring Compounds, Part I
 PubMed  PMC  PDF  Full Text
Tocotrienols: Exciting Biological and Pharmacological Properties of Tocotrienols and Naturally Occurring Compounds, Part II
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

FAM83D and Malignant Tumors: A Brief Literature Review
 Abstract  PDF  Full Text
Treatment of Lower Limb Movement Disorder in Complete Paraplegia Caused by Spinal Cord Injury with Spinal Neuromodulation: A Case Report
 PDF  Full Text
View More...